Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: weatherproof who wrote (38496)	1/7/2017 1:47:09 PM
From: dorightbythem	Read Replies (1) of 63290

This bares repeating, " My fear is that our voices will become less significant relative to the alliance most likely in place already amongst big pharma, institutional investors, and venBio. Once venBio gains control, we've outlived our usefulness for them. " The odds are greater than 50/50 against 132 getting AA, however, if results hold up 132 does stand a chance for FDA approval based on unmet need and no current SOC for TNBC. We have seen that the results for 132 improve drastically in combination therapy with an inhibitor but that would add years and $s to an approval of 132. The odds are greater than 50/50 that the Company will not exist as an independent entity if 132 gets AA much less exist all the way to NDA before it is gobbled up through acquisition. 2017 M&A outlook for mid-market pharma: dealmaking will continue to be a key growth strategy Growing competition will continue to make companies acquisitive Consolidation in the pharma industry was prevalent as big, medium and small pharma players sought dealmaking. While giant pharma deals dominated the headlines this year with Pfizer/Medivation, AbbVie (NYSE: ABBV)/Stemcenrix and Abbott (NYSE: ABT)/St Jude completing multi-billion dollar deals, small and mid-market pharmas also pressed on with their ambitious expansion strategies by pursuing M&A transactions. As competition from big pharma in pursuit of blockbuster drugs increases, we can anticipate companies in the mid-market to seek bolt-on deals or outright mergers to allow them to keep up with consolidating rivals and respond to the changing dynamics of the market. thepharmaletter.com An IMAP Industry Report: GLOBAL M&A Report Pharma / Biotech 2016 imap.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next